Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5N1 virus-like particle vaccine + GLA-SE
- Development stage
- Unknown
- Lead developer
- Medicago
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
The H5N1 virus-like particle (VLP) vaccine combined with the adjuvant GLA-SE is an investigational prophylactic influenza vaccine designed to protect against avian influenza A (H5N1). The VLP component mimics the structure of the native virus, presenting hemagglutinin antigens to elicit immune responses without containing viral genetic material. The adjuvant, glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE), is a synthetic TLR4 agonist formulated in an oil-in-water emulsion that enhances both humoral and cell-mediated immunity by activating innate immune pathways, including TLR4 signaling and NLRP3 inflammasome activation. This combination induces robust antibody production as well as Th1-type CD4+ T cell responses. Developed primarily by Medicago, this candidate has been evaluated in Phase 2 clinical trials for safety and immunogenicity in healthy adults[1][3][6].
- Other names
- H5-VLP + GLA-SEPlant-made H5VLP + GLA-SE
02
Targets
HA (Hemagglutinin)NeuraminidaseTLR4 (Toll-like receptor 4)HN (Hemagglutinin-neuraminidase protein)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on H5N1 virus-like particle vaccine + GLA-SE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5N1 virus-like particle vaccine + GLA-SE.